Distribution of hepatitis C virus genotypes in a diverse US integrated health care population

Journal of Medical Virology

Volumn 84, Issue 11, 2012, Pages 1744-1750

  Manos, M Michele ^a   Shvachko, Valentina A ^a   Murphy, Rosemary C ^a   Arduino, Jean Marie ^b   Shire, Norah J ^b  

^a DIVISION OF RESEARCH   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Epidemiology; Genotype; Geographic distribution; HCV; Hepatitis C

Indexed keywords

VIRUS RNA;

ADULT; AGED; ARTICLE; CROSS-SECTIONAL STUDY; FEMALE; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTEGRATED HEALTH CARE SYSTEM; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONHUMAN; RACE DIFFERENCE; SEX DIFFERENCE; UNITED STATES; VIRUS HEPATITIS;

ADULT; AGE DISTRIBUTION; AGED; CALIFORNIA; CROSS-SECTIONAL STUDIES; ETHNIC GROUPS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; SEX DISTRIBUTION;

HEPATITIS C VIRUS;

EID: 84866509818     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23399     Document Type: Article

References (35)

1. Alter MJ. 2007. Epidemiology of hepatitis C virus infection. World J Gastroenterol 13:2436-2441.
2. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. 1999. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341:556-562.
3. Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, Gadano A, Zein N, Lai CL, Pawlotsky JM, Heathcote EJ, Dusheiko G, Marcellin P. 2010. The neglected hepatitis C virus genotypes 4, 5 and 6: An international consensus report. Liver Int 30:342-355.
4. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Hirakawa M, Ikeda K, Kumada H. 2009. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 49:739-744.
5. Backus LI, Boothroyd DB, Phillips BR, Mole LA. 2007. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 46:37-47.
6. Balagopal A, Thomas DL, Thio CL. 2010. IL28B and the control of hepatitis C virus infection. Gastroenterology 139:1865-1876.
7. Blatt LM, Mutchnick MG, Tong MJ, Klion FM, Lebovics E, Freilich B, Bach N, Smith C, Herrera J, Tobias H, Conrad A, Schmid P, McHutchison JG. 2000. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat 7:196-202.
8. Bruno S, Camma C, Di Marco V, Rumi M, Vinci M, Camozzi M, Rebucci C, Di Bona D, Colombo M, Craxi A, Mondelli MU, Pinzello G. 2004. Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: A randomized controlled trial. J Hepatol 41:474-481.
9. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C. 2004. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 351:451-459.
10. Di Bisceglie AM. 2000. Natural history of hepatitis C: Its impact on clinical management. Hepatology 31:1014-1018.
11. Donlin MJ, Cannon NA, Aurora R, Li J, Wahed AS, Di Bisceglie AM, Tavis JE. 2010. Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients. PLoS ONE 5:e9032.
12. Echevarria JM, Leon P, Pozo F, Avellon A. 2006. Follow-up of the prevalence of hepatitis C virus genotypes in Spain during a nine-year period (1996-2004). Enferm Infecc Microbiol Clin 24:20-25.
13. Esteban JI, Sauleda S, Quer J. 2008. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 48:148-162.
14. Fleckenstein J. 2004. Chronic hepatitis C in African Americans and other minority groups. Curr Gastroenterol Rep 6:66-70.
15. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982.
16. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401.
17. Giordanino C, Bugianesi E, Smedile A, Ciancio A, Abate ML, Olivero A, Pellicano R, Cassader M, Gambino R, Bo S, Ciccone G, Rizzetto M, Saracco G. 2008. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: Results of a cohort study. Am J Gastroenterol 103:2481-2487.
18. Gordon N. 2012. Similarity of the Adult Kaiser Permanente Membership in Northern California to the Insured and General Population in Northern California: Statistics from the 2007 California Health Interview Survey. Internal Report: Kaiser Permanente Division of Research.
19. Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ. 2004. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 117:163-168.
20. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. 2004. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 39:1702-1708.
21. Kamal S. 2006. Genotypic variations around the world: Is hepatitis C virus evolving? Curr Hepat Rep 5:142-149.
22. Kramer JR, Kanwal F, Richardson P, Giordano TP, Petersen LA, El-Serag HB. 2011. Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: A national study. Am J Gastroenterol 106:483-491.
23. Krieger N. 1992. Overcoming the absence of socioeconomic data in medical records: Validation and application of a census-based methodology. Am J Public Health 82:703-710.
24. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK. 2010. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial. Lancet 376:705-716.
25. Leung NW. 2002. Management of viral hepatitis C. J Gastroenterol Hepatol 17:S146-S154.
26. Magiorkinis G, Magiorkinis E, Paraskevis D, Ho SY, Shapiro B, Pybus OG, Allain JP, Hatzakis A. 2009. The global spread of hepatitis C virus 1a and 1b: A phylodynamic and phylogeographic analysis. PLoS MED 6:e1000198.
27. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358:958-965.
28. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM. 2010. Telaprevir for previously treated chronic HCV infection. N Engl J Med 362:1292-1303.
29. Muir AJ, Bornstein JD, Killenberg PG. 2004. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 350:2265-2271.
30. Nainan OV, Alter MJ, Kruszon-Moran D, Gao FX, Xia G, McQuillan G, Margolis HS. 2006. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 131:478-484.
31. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin IT, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42:962-973.
32. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J. 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41:1100-1104.
33. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-1109.
34. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, Nelson KE, Strathdee SA, Johnson L, Laeyendecker O, Boitnott J, Wilson LE, Vlahov D. 2000. The natural history of hepatitis C virus infection: Host, viral, and environmental factors. JAMA 284:450-456.
35. World Health Organization. Hepatitis C. WHO fact sheet 164. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/index.html. Accessed August 5, 2011.